Larimar Therapeutics (LRMR) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Surrozen (SRZN) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 82.9% versus a loss of 41.7%. Over five years, SRZN leads with a -73.5% price change compared with -77.3% for LRMR. Surrozen is the larger company by market cap ($338.4 million vs $278.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | SRZN |
|---|---|---|
| Share price | $2.68 | $28.79 |
| Market cap | $278.41M | $338.38M |
| 1-day change | -2.55% | +14.50% |
| YTD return | -27.82% | +11.26% |
| 1-year return | -41.74% | +82.87% |
| 5-year return | -77.31% | -73.48% |
| EPS (TTM) | $-1.99 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $37.83 |
| 52-week low | $2.61 | $11.39 |
| Distance from 52-week high | -58.26% | -23.90% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +437.31% | +68.11% |
| Average volume | 1.31M | 475.02K |
| Shares outstanding | 103.88M | 11.75M |
| Employees | 71 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed LRMR by 124.6 percentage points over the past year.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
LRMR vs SRZN FAQ
Which is bigger, Larimar Therapeutics or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $338.38M compared with $278.41M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, LRMR or SRZN?
SRZN returned +82.87% over the past 12 months, compared with -41.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Larimar Therapeutics and Surrozen in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Larimar Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Surrozen.